Please fill out the form below and we will gladly respond as soon as possible.
UI Health Care has begun treating eligible patients with synovial sarcoma using a new form of immunotherapy known as T cell receptor (TCR) therapy. This treatment approach represents an important step forward in expanding access to innovative options for people facing advanced synovial sarcoma. A targeted immune-based approach TCR therapy is designed to help the […]
Researchers have studied prasterone—also known as DHEA (dehydroepiandrosterone)—as a potential treatment option for people with synovial sarcoma that has spread (metastatic) or cannot be removed through surgery. This clinical study was designed to better understand the safety of prasterone, determine appropriate dosing, and explore whether it could help slow or control disease progression. This trial […]
The Synovial Sarcoma Foundation is pleased to highlight a significant milestone at the Children’s Hospital of Philadelphia (CHOP), where pediatric oncologist and Synovial Sarcoma Foundation Board Member, Dr. Theodore W. Laetsch, has been awarded a prestigious $1 million multi-year grant from the National Cancer Institute (NCI). This funding aims to accelerate research and treatment development […]
The Synovial Sarcoma Foundation is committed to staying informed on the latest research and developments in this rare and aggressive cancer. A recent market report indicates that the global synovial sarcoma market is projected to grow significantly, reaching an estimated USD 420 million by 2034 — up from USD 245 million in 2024, at a […]